MHRA – Page 184 – Pharma.Tips

Hold Time Bioburden Rise after supplier change: GMP documentation for FDA/EMA/MHRA review

Investigation of Increased Bioburden Hold Times Following a Supplier Change Bioburden testing is pivotal in ensuring the quality and safety of pharmaceuticals, particularly in sterile environments. After a recent supplier…

Viscosity Drift at accelerated stability: packaging compatibility and shelf-life justification

Investigating Viscosity Drift During Accelerated Stability Testing: Ensuring Packaging Compatibility and Shelf-Life Justification Viscosity drift observed during accelerated stability tests can indicate underlying issues impacting product quality and regulatory compliance…

Tube Leakage Complaint after supplier change: QMS trending and complaint handling expectations

Addressing Tube Leakage Complaints Following Supplier Changes in Pharmaceutical Manufacturing In the pharmaceutical manufacturing environment, changes in suppliers can lead to unforeseen issues, including product complaints such as tube leakage.…

Content Uniformity Failure during method transfer: sampling and mixing controls for QA review

Addressing Content Uniformity Failures during Method Transfer: A Comprehensive Investigation Guide Content uniformity failures during method transfer can present significant challenges in pharmaceutical manufacturing, especially in quality assurance. Such failures…

Viscosity Drift during method transfer: GMP documentation for FDA/EMA/MHRA review

Understanding Viscosity Variations during Method Transfers: A Guide for Pharmaceutical Professionals Viscosity drift during method transfer can compromise product quality and regulatory compliance. It may arise from process modifications, equipment…

Assay Oos after supplier change: manufacturing vs lab root cause assessment

Investigating Assay OOS After a Supplier Change: A Comprehensive Approach In the realm of pharmaceutical manufacturing, an Out of Specification (OOS) result, especially concerning assays, can trigger significant concern and…

Pet Failure during bulk hold: GMP investigation steps with CAPA

Steps for Investigating Pet Failure During Bulk Hold in Pharmaceutical Manufacturing In the realm of pharmaceutical manufacturing, encountering a Pet failure during bulk hold can lead to significant challenges, impacting…

Preservative Miscalculation after supplier change: investigation steps with CAPA evidence

Addressing Preservative Miscalculation Following a Supplier Change: A Detailed Investigation Guide In the complex world of pharmaceutical manufacturing, a preservative miscalculation can lead to significant quality control challenges, especially after…

Tag: MHRA

Hold Time Bioburden Rise after supplier change: GMP documentation for FDA/EMA/MHRA review

Viscosity Drift at accelerated stability: packaging compatibility and shelf-life justification

Tube Leakage Complaint after supplier change: QMS trending and complaint handling expectations

Content Uniformity Failure during method transfer: sampling and mixing controls for QA review

Viscosity Drift during method transfer: GMP documentation for FDA/EMA/MHRA review

Assay Oos after supplier change: manufacturing vs lab root cause assessment

Pet Failure during bulk hold: GMP investigation steps with CAPA

Preservative Miscalculation after supplier change: investigation steps with CAPA evidence

Fill Weight Variability in dental gel manufacturing: QMS trending and complaint handling expectations

Texture Grittiness Complaint during bulk hold: sampling and mixing controls for QA review

Texture Grittiness Complaint after packaging change: GMP investigation steps with CAPA

Sedimentation Oos during line setup: packaging integrity and stability justification